Effects of ultra dose vitamin D supplementation on remission, morbidity and mortality of ventilator associated pneumonitis (VAP) patients: A Randomized Controlled Trial study.

Shiraz University of Medical Sciences0 个研究点目标入组 42 人开始时间: 待定最近更新: 2020年6月15日

适应症

试验速览

暂无简介。

•Pneumonia Severity Index (PSI) score above 51
•The level of vitamin D below 20 ng/ml at the admission to the hospital
•Absence of hypercalcemia at the admission to the hospital (calcium concentration above 10.8 mg/dl)
•Stable hemodynamic status
•Not consuming hydrochlorothiazide, digoxin and magnesium containing antacids
•Absence of history of consuming vitamin D during the past four months with the dose above 1000 units
•Able to be be fed enterally at the 24 to 48 hours from the admission time
•Signing the consent form by the family of patients
•Absence of any of these disease: hyperparathyroidism, nephrolithiasis, sarcoidosis, chronic kidney disease, cirrhosis, metabolic diseases, acquired immune deficiency syndrome (AIDS), cardiovascular disease, diabetes mellitus, cancers and autoimmune diseases
•Not being pregnant
•Not involved in other research projects

•Presence of other types of pneumonitis
•Dying earlier than 7 days of intervention
•Presence of any condition leading to enteral feeding disruption during the first 5 days of intervention
•If the supplementation is thought to be hazardous or being forbidden by the general practitioner

发起方